The assignee ranking in this dataset is led by a single academic institution holding 694 of the 2,560 records in scope, well ahead of the field. The top five assignees together account for 78.5% of all records, and the top ten reach 95.2%, so ownership is heavily concentrated among a small group of academic and biotech filers rather than spread across many independent companies. Anyone assessing freedom to operate in this space should start with that concentrated group before looking at the long tail of single- or few-filing entrants.

Filings rose from 115 in 2017 to a peak of 353 in 2021, then eased to 247 by 2024 — a -30% move over that complete three-year window. That should be read as a cooling from an unusually dense peak year rather than a broad retreat, because the technology and its co-filing pairs remain active. Figures for 2025 and 2026 are still filling in, since publication trails filing by roughly 18 months, so it is too early to call a trend from those years.

WO2025226816A1, filed by the Christiana Care Gene Editing Institute and published 2025-10-30, discloses methods of identifying a guide RNA that induces exon skipping in a target gene, plus methods of inducing that exon skipping and controlling the heterogeneity of the resulting phenotypic outcome. It sits closer to the outcome-measurement layer than to the core editing chemistry — it is about correlating a CRISPR-induced skipping event with a phenotypic result, not about a novel guide RNA chemistry itself. Anyone working on exon-skipping guide design or phenotype-outcome assays should read its claim scope directly rather than assume it only covers guide RNA composition.